These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26106466)

  • 21. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand.
    Prapitpaiboon H; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2015; 16(10):4353-6. PubMed ID: 26028098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study].
    Gao W; Cheng H; Hu FL; Lü NH; Xie Y; Sheng JQ; Xu JM; Zhang LX; Zhang L; Chen Y; Zhang ZY; Zhang GX; Cui MH; Yang GB; Gao HJ; Yang L
    Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(30):2108-12. PubMed ID: 23158273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of ranitidine bismuth citrate plus amoxycillin and clarithromycin as first- or second-line therapy to cure Helicobacter pylori infection.
    Tursi A; Brandimarte G; Giorgetti G; Modeo ME; Gigliobianco A
    Hepatogastroenterology; 2002; 49(46):1006-9. PubMed ID: 12143188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication.
    Gisbert JP; Marcos S; Gisbert JL; Pajares JM
    Helicobacter; 2001 Jun; 6(2):157-62. PubMed ID: 11422472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Helicobacter pylori eradication with ecabet sodium, omeprazole, amoxicillin, and clarithromycin versus bismuth, omeprazole, amoxicillin, and clarithromycin quadruple therapy: a randomized, open-label, phase IV trial.
    Liang J; Li J; Han Y; Xia J; Yang Y; Li W; Zhang S; Wu Y; Yuan Y; Li Z; Du Y; Chen M; Chen B; Jiang B; Bai Y; Wen Q; Wu K; Fan D
    Helicobacter; 2012 Dec; 17(6):458-65. PubMed ID: 23066868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzalez B; Sgouras DN; Spiliadi C; Mentis AF; Laoudi F
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
    Nagahara A; Miwa H; Ogawa K; Kurosawa A; Ohkura R; Iida N; Sato N
    Helicobacter; 2000 Jun; 5(2):88-93. PubMed ID: 10849057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 7- and 14-Day Eradication Therapy for
    Kim TH; Park JM; Cheung DY; Oh JH
    J Korean Med Sci; 2020 Feb; 35(5):e33. PubMed ID: 32030921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease].
    Veliev AM; Maev IV; Andreev DN; Dicheva DT; Zaborovskii AV; Lobanova EG; Bektemirova LG
    Ter Arkh; 2019 Aug; 91(8):28-33. PubMed ID: 32598751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
    Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
    Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
    Avşar E; Tiftikçi A; Poturoğlu S; Erzin Y; Kocakaya O; Dinçer D; Yıldırım B; Güliter S; Türkay C; Yılmaz U; Onuk MD; Bölükbaş C; Ellidokuz E; Bektaş A; Taşan G; Aytuğ N; Ateş Y; Kaymakoğlu S
    Turk J Gastroenterol; 2013; 24(4):316-21. PubMed ID: 24254262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates.
    Sotudehmanesh R; Malekzadeh R; Fazel A; Massarrat S; Ziad-Alizadeh B; Eshraghian MR
    J Gastroenterol Hepatol; 2001 Mar; 16(3):264-8. PubMed ID: 11339416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy.
    Ebrahimi-Dariani N; Mirmomen S; Mansour-Ghanaei F; Noormohammadpoor P; Sotodehmanesh R; Haghpanah B; Bahrami H
    Med Sci Monit; 2003 Aug; 9(8):PI105-8. PubMed ID: 12942042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
    Fakheri H; Malekzadeh R; Merat S; Khatibian M; Fazel A; Alizadeh BZ; Massarrat S
    Aliment Pharmacol Ther; 2001 Mar; 15(3):411-6. PubMed ID: 11207517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helicobacter pylori and gastric or duodenal ulcer.
    Prescrire Int; 2016 Jan; 25(167):18-23. PubMed ID: 26942258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication.
    Ye JF; Hong JB; Zhu Y; Xie Y; Shu X; Luo LY; Xie C; Zhu ZH; Lu NH
    J Dig Dis; 2017 Dec; 18(12):704-708. PubMed ID: 29119724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.